[Amphotericin B and its lipid formulations].
More than 40 years after its approval, Amphotericin B is still the gold standard in the treatment of invasive fungal infections due to Candida and Aspergillus spp. Three different lipid formulations of Amphotericin B have been available for over 10 years, with only one of them, i.e. liposomal Amphotericin B (Ambisome), approved in Germany. Liposomal Amphotericin B is superior to conventional Amphotericin B due to its reduced nephrotoxicity, the option of a higher initial loading-dose, and fewer infusion-related side-effects, all this with identical or even higher efficacy.
Ritter
J
J
Klinik und Poliklinik für Kinderheilkunde, Pädiatrische Hämatologie/Onkologie, Albert-Schweitzer-Str. 33, 48149 Münster, Deutschland. ritterj@uni-muenster.de
D000666:Amphotericin B / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D001230:Aspergillus / Q000187:drug effects; D002175:Candida / Q000187:drug effects; D004338:Drug Combinations; D006801:Humans; D008081:Liposomes / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D010713:Phosphatidylcholines / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000627:therapeutic use
D000935:Antifungal Agents; D004338:Drug Combinations; D008081:Liposomes; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B
Amphotericin B und seine Lipid-Formulierungen.